Is HEXO a Good Cannabis Stock to Buy Now?

Should investors confidently buy HEXO stock before the upcoming $1.2 billion equity raise?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Canadian marijuana producer HEXO (TSX:HEXO)(NYSE:HEXO) is expected to raise up to $1.2 billion in new equity within the next 25 months. The company could significantly dilute its existing shareholders, but investors didn’t seem too concerned judging from the company’s stock price performance, since the news broke out on Thursday evening.

Perhaps it’s too early for investors to price in any dilution discounts, as the company won’t necessarily raise $1.2 billion in one big transaction. Money will be raised “from time to time.” That said, markets are forward looking. They price a stock based not on its past earnings, but on its expected future earnings and cash flows. So, the potential dilution should already be priced in by now. But I believe it may not be, given missing information.

HEXO stock price VS Canadian peers since filing a $1.2 billion base shelf prospectus on April 15.
HEXO shares prove resilient. The market can’t confidently put a dilution discount on the TSX marijuana stock yet.

The company registered its intention to issue stock, but we don’t know much yet. We aren’t sure about the actual timing of equity raises over the 25-month window. The new partners aren’t disclosed either. Of course, some of the upcoming deals will focus on a U.S.-led expansion strategy, but the company could announce Canada-based ventures, too. Some of the cash could even go into acquisitions, and the company could raise much less than $1.2 billion. It may allow the prospectus to expire as it has previously done.

Should you buy HEXO stock before its $1.2 billion equity raise?

There are many unknowns as far as the decision to buy HEXO shares is concerned at this point.

As previously mentioned, “the decision whether to buy more HEXO stock as it dilutes shareholders should therefore be influenced by two things: one’s faith in management and an assessment of U.S. regulatory changes and market potential for amplified revenue and cash flow growth.”

I have no problems with the management component at the moment. The team was the first to take drastic action and quickly refocus operations when it became apparent that the marijuana market was not growing as big as initially expected. They turned around the company, and it reported its first positive adjusted EBITDA quarter by January 2021.

Most noteworthy, the company has made good progress with previously announced partnerships. This validates management’s capability to execute its partnerships-led strategy.

Previous successes through strategic partnerships

The company’s cannabis-infused beverages partnership (the Truss Beverage Company) with Molson Coors Canada has been accretive to growth. Since its launch four quarters ago, revenue from beverage sales has increased from just 2% of total company net revenue by April 2020 to over 10.3% of net sales by January this year.

Notably, sales grew in other segments during the period. Holding other segments’ quarterly sales constant at April 2020 levels, Truss’s quarterly sales could have constituted 15% of quarterly revenue by January this year. The joint venture claims market leadership in Canada. In just one year of beverage sales, HEXO has added 15% growth to its top line with just one partner.

The company has another joint venture deal that has constructed a cannabinoid extraction factory. The joint venture, Keystone Isolation Technologies (KIT), provides the company with a platform onto which it can enroll new product and brand development partners.

HEXO is thus proven technically capable of bringing new successful products to the market through partnerships. The Powered by HEXO platform is about to bring on board new international consumer packaged goods partners. The focus, as I see it, is on the U.S. CBD market where the company is actively establishing a long-term presence.

That said, the U.S. CBD market still has its marketing challenges with the FDA. However, this did not stop the Truss partnership from launching in Colorado. The company also aims to establish extraction centres in America modeled after its KIT facility in Canada. The technology could easily switch from hemp CBD to cannabis processing once it becomes federally legal to do so.

The company is placing its best foot forward into the U.S., even as its Canadian peers do the same.

Foolish bottom line

The company has successfully incubated partnership projects. Banking on previous successes, management’s execution risk is lower. However, until we get more details, any investment actions based mostly on HEXO’s latest filing are highly speculative.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends HEXO.

More on Cannabis Stocks

Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »